Orange County NC Website
Browse       Search
2 <br />CONFIDENTIAL <br />11122019 <br />“Future dated Product” shall mean products that have not yet expired and have the potential to age and be <br />returnable at a date in the future according to the manufacturer return policy. <br />“Viable product” shall mean any product that is in the original manufacturer packaging or that has the <br />reasonable expectation of return credit according to the manufacturer’s returned goods policy. <br />“Non-Viable product” is defined as a pharmaceutical that cannot be sold, returned to the manufacturer, <br />wholesaler or reverse distributor with a reasonable expectation of credit, or donated to a charitable <br />organization. This includes but is not limited to any product: (1) labeled “Not for Resale,” “Sample,” <br />“Damaged,” or “Repackaged,” (2) that is void of inventory, (3) that has been dispensed outside of the <br />original manufacturer packaging, (4) that has no reasonable expectation of credit according to the <br />manufacturer’s return policy, and (5) considered medical waste, sharps, raw materials and/or chemicals <br />used in compounding, compounded liquids, creams, or gels, biohazardous waste, or aerosols. <br />I.Summary of Services <br />PLI shall perform the services as set forth in this SOW in compliance with all applicable federal, state and <br />local laws, rules, and regulations. <br />II.Deliverables <br />•PLI <br />o Detailed Return Inventory reports. <br />o Certificates of Destruction. <br />o Non-returnable Inventory Reports. <br />o Corporate Level Reports upon request. <br />•Customer <br />o Monthly report of credits received directly from manufacturer or wholesaler for return <br />product processed by PLI. <br />III.Obligations of PLI <br />PLI shall provide Company with Pharmaceutical Return and Disposal Services, including but not limited to: <br />•Ground shipping, via common carrier, from the returning facility to the PLI processing facility. <br />•Processing of returned products to determine credit eligibility according to the manufacturer’s <br />and/or wholesaler’s Returned Goods Policy. <br />•Shipment of returnable product to pharmaceutical manufacturer for credit. <br />•Sortation, characterization, and profiling of non-returnable merchandise. <br />•Disposal of non-returnable products via incineration. <br />•Application and execution of product return authorizations. <br />•Product staging and handling. <br />•Detailed return inventory reports and certificates of destruction. <br />•Access to web-based inventory and reporting applications. <br />•Storage and tracking of Future dated product. <br />a.Manufacturer Return Process <br />1.PLI will obtain and complete all manufacturers’ return authorizations. <br />2.Through standard returns processing, the manufacturer issues the following types of credit: <br />•wholesaler credit, <br />•direct reimbursement check, or <br />•exchange product. <br />Docusign Envelope ID: 550F0A34-DEE8-4FFA-B72D-1ABBE467C60B